Supporting evidence
Pioglitazone × Proportion achieving HbA1c <7.0%
- Authoritative support
- 3
- Available studies
- 3
- Unavailable support
- 0
Available supporting studies
Study 1 · Included
Lobeglitazone improves glycaemic control in type 2 diabetes patients
Rct
- Comparison
- Patients received lobeglitazone as an add on treatment for type 2 diabetes. · Patients received a placebo as a comparator to lobeglitazone.
- Duration / follow-up
- 52 weeks
Relevant effects
Mean difference
0.71 · 0.001
Percent change
35.3 · 0.001
Mean difference
0
Percent change
0
Study 2 · Included
Pioglitazone improves glycemic control compared to dapagliflozin in type 2 diabetes
Rct
- Comparison
- Patients received pioglitazone (25 mg/15 mg) once daily, along with metformin twice daily. · Patients received dapagliflozin (10 mg) once daily, an alogliptin tablet (25 mg) once daily, and metformin tablets twice daily.
- Duration / follow-up
- 4 weeks
Relevant effects
Mean difference
0.75
Mean difference
0.88
Study 3 · Limited
Pioglitazone improves remission of hyperglycemia in early-stage type 2 diabetes
Rct
- Comparison
- Patients receiving intensive lifestyle modification with nutritional guidance by a managerial dietician. · Patients receiving pioglitazone in addition to conventional diet therapy. · Patients receiving sulfonylurea in addition to conventional diet therapy.
- Duration / follow-up
- 156 weeks
Relevant effect
Percent change
30 · 0.001